ASCO 2012
ASCO 2012 Practice-Changing Research on Prostate Cancer Presented at ASCO 2012: With Commentary by Dr Neal Shore

Practice-Changing Research on Prostate Cancer Presented at ASCO 2012: With Commentary by Dr Neal Shore

This article reviews the most significant research on prostate cancer presented last month at ASCO 2012, with commentary from Dr Neal Shore.

ASCO 2012 Dr. Sergio A. Giralt Offers Commentary on Hematologic Oncology Coverage at ASCO 2012

Dr. Sergio A. Giralt Offers Commentary on Hematologic Oncology Coverage at ASCO 2012

Initial salvage treatment with allogenic stem cell transplant (ASCT) is feasible and yields superior outcomes to salvage chemotherapy in acute myeloid leukemia (AML) patients.

ASCO 2012

Phase 3 Study Shows Abiraterone Improves Survival in Prostate Cancer

Abiraterone acetate (AA) plus prednisone (P) produced a statistically significant improvement in radiographic progression-free survival (rPFS) and a strong trend for increased overall survival (OS), according to the results of a study presented by a multinational team of researchers at the 2012 American Society of Clinical Oncology Annual Meeting.

ASCO 2012

Dr. Barbara Burtness at ASCO 2012 on Head and Neck Cancer

Dr. Barbara Burtness is a physician-scientist of the Fox Chase Cancer Center and an expert in the treatment of head and neck cancer.

ASCO 2012

Maintenance Gemcitabine plus Paclitaxel Chemotherapy Offers Improved Outcomes in Metastatic Breast Cancer

Maintenance chemotherapy with the combination of gemcitabine and paclitaxel (GP) following clinical response to GP is associated with improved survival times.

ASCO 2012

Weekly Paclitaxel Remains Standard Regimen for First-Line Treatment of Metastatic Breast Cancer

Neither weekly nab-paclitaxel nor ixabepilone are superior to weekly paclitaxel in patients with chemotherapy-naïve advanced breast cancer receiving bevacizumab.

ASCO 2012

ASCO: Duloxetine is Effective and Well-Tolerated for Treatment of Chemotherapy-Induced Peripheral Neuropathy (CIPN)

Daily duloxetine therapy effective and well-tolerated for the treatment of CIPN.

ASCO 2012

ASCO: Radium-223 Prolongs Survival Time for Patients with Bone-Metastatic Castration-Resistant Prostate Cancer

Radium-223 chloride therapy significantly prolongs median OS time for men with castration-resistant prostate cancer (CRPC) bone metastasis.

ASCO 2012

Weekly Paclitaxel After Adjuvant FAC Modestly Improves DFS in High-Risk, Node-Negative Breast CA Patients

Adding weekly paclitaxel to adjuvant FAC therapy offers a modest improvement in disease-free survival for patients with high-risk, node-negative breast cancer.

ASCO 2012

Crizotinib Shows Strong Efficacy and Tolerability in Patients with ALK-positive NSCLC

Crizotinib has a strong response rate, progression-free survival (PFS), and is well tolerated in patients with ALK-positive non-small cell lung cancer (NSCLC).

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs